Inspire Medical Receives FDA Approval For Next Generation Inspire Neurostimulation System

(RTTNews) - Inspire Medical Systems, Inc. (INSP) announced on Friday that it has obtained FDA approval for Inspire V therapy system, its next generation Inspire neurostimulation system, for moderate to severe obstructive sleep apnea.

The Inspire V therapy system features the next generation neurostimulator, a Bluetooth-enabled patient remote, and a physician programmer.

The company stated that it intends to initiate a soft launch in late 2024, followed by a full launch in 2025 in the U.S. market.

In pre-market activity on the NYSE, the shares are trading at $137.90, up 4.97%.